Trevi Therapeutics (TRVI) PT Lowered to $10 at Stifel

Stifel analyst Annabel Samimy lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $10.00 (from $14.00) while maintaining a Buy rating.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced earlier today the completion of the pre-specified sample size re-estimation (SSRE) analysis for the ongoing PRISM Phase 2b/3 trial of Haduvio for severe pruritus in patients with prurigo nodularis (PN)."Based on the SSRE analysis the independent Data Monitoring Committee (DMC) recommended that the PRISM trial should continue and that the trial size should increase from an initial enrollment target of 240 to 360 subjects which maintains the statistical power for the primary endpoint. The DMC’s recommendation was based on a pre-specified interim conditional power assessment conducted after approximately 45% of the initial targeted number of patients were evaluable for the primary endpoint of the trial. Based on the DMC’s recommendation, the Company plans to increase the size of the trial to 360 subjects," the pressrelease stated.

You May Also Be Interested In

• AGNC Investment Corp (AGNC) PT Lowered to $10.25 at Jones Trading
• LG Chem Ltd (051910:KS) (LGCLF) PT Lowered to KRW460,000 at JPMorgan
• JetBlue Airways (JBLU) PT Lowered to $6 at TD Cowen